Navigation Links
Fifteenth US Patent Issued for aTyr Pharma Novel Biotherapeutic
Date:9/9/2009

SAN DIEGO, Sept. 9 /PRNewswire/ -- aTyr Pharma announced today that the US Patent office has issued patent US 7,572,452 B2, titled "Method for Stimulating Wound Healing." aTyr Pharma is the sole assignee of this patent, and Professor Sunghoon Kim, a scientific co-founder of aTyr Pharma, is the inventor. An example of aTyr Pharma's broad intellectual property portfolio and the fifteenth filed patent related to aTyr Pharma's work in tRNA synthetases, this patent covers new extracellular activities for p43, a critical protein component of the multi-aminoacyl tRNA synthetase complex in humans. The aminoacyl tRNA synthetases are universal and essential elements of the protein synthesis machinery found in all organisms, but human synthetases and their associated proteins have naturally occurring resected variants, called "resectins," with potent cell signaling activities that are vital to normal functioning of humans. The resectins' activities are distinct from the protein synthesis activities commonly known for synthetases, and aTyr Pharma is discovering and developing the resectins as new biotherapeutic agents that can be used to treat a wide variety of human diseases including inflammatory, autoimmune, hematopoietic and metabolic disorders.

Jeff Watkins, CEO of aTyr Pharma, had this to say about the patent: "This patent covers discoveries Professor Kim has made for extracellular activity of the p43 component of the multi-sythetase complex. As part of aTyr Pharma's portfolio, this patent helps establish our dominant ownership and leadership in the resectin space. Capitalizing on this new area of biology, we are identifying and developing these naturally occurring resectins as candidate biotherapeutics for treating a wide variety of diseases."

Professor Kim, of Seoul National University in Korea, has had a long scientific relationship with Professor Paul Schimmel of The Scripps Research Institute and a co-founder of aTyr Pharma. According to Professor Schimmel, "Professor Kim's research has really helped build our understanding of how far-reaching the non-canonical functions are for naturally occurring resectins of tRNA synthetases and their associated proteins. This newly issued patent highlights the innovation surrounding the discovery and development of tRNA synthetase resectins as biotherapeutics." Professors Schimmel and Kim recently co-authored a scientific article in the Proceedings of the Natural Academy of Sciences (PNAS USA, 2008, vol. 105: 11043-11409) describing many of the newly emerging functions of tRNA synthetases and the relationships to human medicine.

Link to the PNAS review article: http://www.pnas.org/content/105/32/11043.full.pdf

About aTyr Pharma

aTyr Pharma, Inc. is a biopharmaceutical company focused on the discovery and development of an entirely new class of biologics. aTyr Pharma's discovery engine for new biotherapeutics consists of novel proteins in the family of tRNA synthetases with cell signaling activities distinct from the protein synthesis activities commonly associated with the tRNA synthetases. These resected proteins, or "resectins," are being developed as novel therapeutics to treat hematological disorders, neurodegenerative diseases, inflammation, cardiovascular diseases and metabolic disorders.

www.atyrpharma.com


'/>"/>
SOURCE aTyr Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Fifteenth Annual Pridelights Goes Green
2. Genova files patent for new prostate cancer treatment
3. Caraco Pharmaceutical Laboratories, Ltd. Announces Reversal of Summary Judgment in Ultracet(R) ANDA Patent Litigation
4. TANCS Steam Vapor Granted U.S. Patent
5. Milestone Scientific Announces Notice of Allowance From US Patent and Trademark Office
6. Palomar Successful in U.S. Patent Office Re-Examination of Second Hair Removal Patent
7. Secure eHealth Partner Receives Patent and Notice of Patent Allowance that is Key to Enriched Data Portability in Healthcare
8. U.S. District Court Rules Against Lilly Regarding Gemzar Patent
9. Hard To Treat Diseases (HTDS.PK) Completes IP Ownership Filings With U.S. Patent and Trademark Office
10. German District Court Rules in Smith & Nephews Favor in Patent Infringement Case
11. AlphaRx Receives China Patent on Its Drug Delivery Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star ... , Millions of individuals in the United States and Canada wear eyeglasses. Once considered ... both correct vision and make a fashion statement. Even celebrities use glasses as a ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a ... and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is ... to some of the world’s leading providers of cereal and other breakfast foods. Its ...
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: